Terms: = Ovarian cancer AND KDM5A, RBBP2, 5927, JARID1A, ENSG00000073614 AND Clinical Outcome
1 results:
1. kdm5a Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in ovarian cancer.
Liu H; Lin J; Zhou W; Moses R; Dai Z; Kossenkov AV; Drapkin R; Bitler BG; Karakashev S; Zhang R
Cancer Immunol Res; 2022 Aug; 10(8):1028-1038. PubMed ID: 35726891
[TBL] [Abstract] [Full Text] [Related]
